Statins and fibrates for preventing melanoma (Q24245521)

9 December 2023

Amanda Drake

2

A

Drake

1 reference

9 December 2023

Marla Graber

3

M

Graber

1 reference

9 December 2023

Lauren Pointer

4

0 references

Kathryn Johnson

5

K R

Johnson

1 reference

9 December 2023

Kristie McNealy

6

K

McNealy

1 reference

9 December 2023

Lisa Schilling

7

L

Schilling

1 reference

9 December 2023

L F Heilig

L F

Heilig

4

1 reference

9 December 2023

E J Hester

E J

Hester

5

1 reference

Cochrane Database of Systematic Reviews

9 December 2023

language of work or name

1 reference

19 October 2005

0 references

published in

0 references

cites work

Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Tr

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The cholesterol and recurrent events trial (CARE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

The Helsinki Heart Study: central findings and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Bezafibrate in men with lower extremity arterial disease: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN4119421

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Design features and baseline characteristics of the LIPID (long-term intervention with pravastatin in ischemic disease) study: A randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project—A combined analysis of three large-scale randomized trials: Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID), Cholesterol and Re

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Effect of cholesterol reduction by simvastatin on progression of coronary atherosclerosis: Design, baseline characteristics, and progress of the Multicenter Anti-Atheroma Study (MAAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-densi

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Rationale and design of the St. Francis Heart Study: a randomized clinical trial of atorvastatin plus antioxidants in asymptomatic persons with elevated coronary calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

STATT: a titrate-to-goal study of simvastatin in Asian patients with coronary heart disease. Simvastatin Treats Asians to Target

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vasc

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Rationale and design for the SARIS trial; effect of statin on atherosclerosis and vascular remodeling assessed with intravascular sonography. Effect of Statin on Atherosclerosis and vascular Remodeling assessed with Intravascular Sonography

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the pravastatin anti-atherosclerosis trial in the elderly (PATE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Design and rationale of the ARBITER trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)--a randomized trial comparing the effects of atorvastatin and pravastatin on carotid artery intima-media thickness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Cerivastatin versus branded pravastatin in the treatment of primary hypercholesterolemia in primary care practice in Canada: a one-year, open-label, randomized, comparative study of efficacy, safety, and cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

The efficacy of atorvastatin in treating patients with hypercholesterolaemia to target LDL-cholesterol goals: the LIPI-GOAL trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Cholesterol inhibition, cancer, and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Cholesterol, primary and secondary prevention, and all-cause mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Melanoma chemoprevention: a role for statins or fibrates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

STUDIES ON LIPIDS IN BRAIN TUMOURS--I

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Inhibition of melanoma metastases by fenofibrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Carcinogenicity of lipid-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Lovastatin-induced apoptosis in human melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

The potential of statins as part of anti-cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Fluorescent lights, ultraviolet lamps, and risk of cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

An estimate of the annual direct cost of treating cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Receptor-mediated uptake of low-density lipoprotein by B16 melanoma cells in vitro and in vivo in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

Newer strategies for effective evaluation of primary melanoma and treatment of stage III and IV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

The 'Ugly Duckling' Sign: Identification of the Common Characteristics of Nevi in an Individual as a Basis for Melanoma Screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

Early detection of melanoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

Estimating treatment effects from observational data: dissonant and resonant notes from the SYMPHONY trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

Coronary drug project: experience with niacin. Coronary Drug Project Research Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

A coronary primary prevention study of Scottish men aged 45-64 years: trial design. The West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

Design & rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

The health impact of solar radiation and prevention strategies: Report of the Environment Council, American Academy of Dermatology

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

A study to determine the response of coronary atherosclerosis to raising low high density lipoprotein cholesterol with a fibric-acid derivative in men after coronary bypass surgery. The rationale, design, and baseline characteristics of the LOCAT St

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

The Helsinki Heart Study: basic design and randomization procedure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

Low total cholesterol is associated with high total mortality in patients with coronary heart disease. The Bezafibrate Infarction Prevention (BIP) Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

Evolution of coronary atherosclerosis in patients with mild coronary artery disease studied by serial quantitative coronary angiography at 2 and 4 years follow-up. The Multicenter Anti-Atheroma Study (MAAS) Investigators

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

The Helsinki Heart Study: an 8.5-year safety and mortality follow-up

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

The Helsinki Heart Study: coronary heart disease incidence during an extended follow-up

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

Semiological value of ABCDE criteria in the diagnosis of cutaneous pigmented tumors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

The treatment of cerebrovascular disease with clofibrate. Final report of the Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

Efficacy and safety of 300 micrograms and 400 micrograms cerivastatin once daily in patients with primary hypercholesterolaemia: a multicentre, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

Angiographic intervention trial using HMG CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma in West Japan (ATHEROMA study): rationale, design and baseline

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg, in patients with primary hypercholesterolaemia: a multinational, randomised, double-blind study. Cerivastatin Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

The Risk of Cancer in Users of Statins

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

The search for cancer risk factors: when can we stop looking?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003697.PUB2

7 January 2021

10.1002/14651858.CD003697.PUB2

Identifiers

DOI

0 references

Fatcat ID

release_dzdatb4vzvfk3khiqjiqmp7u7y

0 references